ArticleClinical rheumatology2026
Association of diagnostic delay with disease activity and cumulative damage in Hispanic patients with idiopathic inflammatory myopathies: a cross-sectional study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIdiopathic inflammatory myopathies (IIM) are rare autoimmune disorders. Their clinical heterogeneity often leads to diagnostic delays, which have been associated with worse outcomes. In individuals with darker skin phototypes, cutaneous signs may be less apparent, further complicating recognition. We aimed to evaluate the association of diagnostic delay with disease activity and cumulative damage in patients with IIM.
methodWe conducted a cross-sectional, comparative study at a tertiary care hospital in Mexico from November 2024 to July 2025. Patients aged 18 years or older diagnosed with IIM were included and classified according to established criteria and a treating rheumatologist's assessment. Data collected included demographics, comorbidities, skin phototype, and serology. Disease activity was measured using the myositis disease activity assessment tool which includes the Myositis Disease Activity Assessment Visual Analog Scale (MYOACT) and the Myositis Intention-to-Treat Activity Index (MITAX) and cumulative damage using the Myositis Damage Index (MDI). Patients were stratified by diagnostic delay, ≤ 5 months, and > 5 months. Statistical analysis included correlation tests and group comparisons.
results53 patients were included, mean age of 45.3 years; 84.6% women. Dermatomyositis was the most frequent subtype (62.2%). Patients with diagnostic delay > 5 months were significantly younger (p = 0.02) and showed higher disease activity (MYOACT p < 0.001; MITAX p = 0.005) and damage (MDI extent p = 0.03). Fitzpatrick phototypes IV-V were more prevalent among patients with longer diagnostic delays (80.7% p = 0.002 vs. 51.8% p = 0.002).
conclusionLonger diagnostic delays in IIM were associated with increased disease activity, functional impairment, and disproportionate impact on younger patients and those with darker skin tones. These findings highlight the need for earlier recognition and equitable diagnostic practices in diverse populations. Key Points •A diagnostic delay ≥ 5 months is associated with greater accumulated damage and disease activity. • A darker skin phototype and a younger age predispose to a longer diagnostic delay. • Delayed diagnosis was associated with worse physical function.
Indexed as
Identifiers
41807676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.